Methods are provided for the detection and treatment of cancers having a KRAS mutation, which KRAS mutation may drive tumorigenesis in the cancer. In some embodiments the KRAS cancer is a lung adenocarcinoma.Arvin GouwDean W. FelsherAlice Fan...
InAsPC-1 (harboring KRAS G12D mutation): ~70% reduction in overall bioluminescence (an indication of tumor cell number) as compared to the control group, by day 28. In Panc-1 (harbouring KRAS G12D mutation): Bioluminescence or tumor cell numbers decreased dramatically in a dose-depend...
Ganoderma microsporum immunomodulatory protein combined with KRASG12C inhibitor impedes intracellular AKT/ERK network to suppress lung cancer cells with KRAS mutation 2024, International Journal of Biological Macromolecules Citation Excerpt : A previous study has demonstrated that GMI manifests a suppressive ...
F. et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin. Cancer Res. 19, 4273–4281 (2013). Article CAS PubMed Google Scholar Sasaki, T. et al. A novel ALK secondary mutation and EGFR ...
Healthcare Sales & Marketing Network: Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Exa
(f) Summary of adjusted p-value for differences in each multi-omic features among subtypes under different clustering strategies. NS: not significant. Mut: mutation. Amp: amplification. Met: metabolite. HRD: homologous recombination deficiency. Bold font indicates the clustering strategy we used. (...
KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. Epidermal growth factor recepto
33,34 However, we also have identified a novel finding of an acquired KRAS mutation, which was confirmed using tumor NGS and plasma droplet digital PCR. The complex variety of resistance mutations seen in patients with loss of T790M, including several acquired fusion genes, highlights the need ...
p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. Radiother Oncol. 2013;109:146–51. 8. Koerber SA, Schoneweg C, Slynko A, Krug D, Haefner MF, Herfarth K, Debus J, Sterzing F, von ...
71 The assay is capable of detecting 0.1% mutation in 10,000 copies of wild-type genomic DNA (gDNA) background.71 Didelot et al. evaluated KRAS, BRAF, and EGFR genotyping by this method on suboptimal FFPE colon and lung cancer samples. Of 63 samples, 60 were correctly genotyped.66 One ...